Format

Send to

Choose Destination
Biochem Biophys Res Commun. 2000 Jan 27;267(3):947-52.

beta3-endonexin as a novel inhibitor of cyclin A-associated kinase.

Author information

1
Department of Viral Oncology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, 170-8455, Japan.

Abstract

Cyclin A is indispensable for S phase cell cycle progression and is suggested to be a crucial target of cell adhesion signals. In this study, we demonstrate that beta3-endonexin, a molecule known to associate with the integrin beta3 cytoplasmic domain, specifically binds cyclin A. Deletion of the amino-terminal 52-amino-acid residues including the cyclin-binding RxL motif abolishes the ability of beta3-endonexin to interact with cyclin A. In an in vitro kinase assay, beta3-endonexin inhibits pRB kinase activity associated with cyclin A-Cdk2 while leaving its histone H1 kinase activity unaffected. Coexpression of beta3-endonexin in yeast cells overcomes growth suppression caused by an activation of cyclin A-associated kinase. Our results indicate that beta3-endonexin is a novel cyclin A-binding molecule that regulates cyclin A-associated pRB kinase activity.

PMID:
10673397
DOI:
10.1006/bbrc.1999.2007
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center